Arialys has been recognized as one of the most innovative startups of 2023! We were chosen for the PM360 Innovations Issue for advancing new precision medicines for autoimmune neuropsychiatric disorders.

Arialys was founded on the breakthrough understanding that immune cells—not only in the body’s periphery but especially in the brain—can produce autoantibodies that cause severe neurological and psychiatric diseases. We look forward to advancing our lead drug candidate, ART5803, into clinical trials next year for the treatment of anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis.

Read more at PM360 Magazine.